Return-Path: <hottpick1@antoine.inserm.fr>
Delivered-To: bfsmedia-gn@bfsmedia.com
Received: (qmail 18620 invoked from network); 23 Feb 2001 18:44:36 -0000
Received: from unknown (HELO hikaridell2.hkr.ne.jp) (210.237.160.22)
  by bfsmedia.sk.ca with SMTP; 23 Feb 2001 18:44:36 -0000
Received: from [210.237.160.1]
          (1Cust198.tnt3.huntsville.al.da.uu.net [63.10.53.198])
          by hikaridell2.hkr.ne.jp (Netscape Mail Server v1.1) with SMTP
          id ADI201; Sat, 24 Feb 2001 00:21:15 +0900
To: nletters@antoine.inserm.fr
Message-ID: <196452734125.GAA51354@antoine.inserm.fr>
Date: Fri, 23 Feb 01 05:13:22 EST
From: hottpick1@antoine.inserm.fr
Subject: STOCK ALERT!  SPHC 58 cents FDA for (HIV/AIDS indication)
Content-Length: 2851
Lines: 59

STOCK ALERT!

(OTCBB:SPHC) FDA Phase Ib/IIa for Anticort(TM) (an HIV/AIDS indication)

HERE IS OUR NEXT EXPLOSIVE STOCK PICK at 58 cents per share!

(OTCBB:SPHC) FDA Phase Ib/IIa for Anticort(TM) (an HIV/AIDS indication)
58 cents per share

Samaritan Pharmaceuticals
OTCBB: SPHC
We rate SPHC a STRONG BUY
BUY AT $ 0.58
SELL TARGET $2.50- $2.75


Samaritan Pharmaceuticals

SPECIAL ALERT (OTCBB:SPHC) announced that its FDA Phase Ib/IIa safety
and efficacy clinical trials under its IND for Anticort(TM) (an HIV/AIDS indication)
at the Aids Research Alliance located in Los Angeles, CA, are expected
to be completed at the end of March or early April.
 
The Company expects it will take approximately three months to compile
and analyze the data from this study and another month or so to ready
the data for submission to the FDA. In anticipation of this process, the
Company has decided to finalize all payments to the Aids Research
Alliance, thereby fulfilling all of its financial responsibility for the Phase
lb/lla clinical trial.

for more details: http://biz.yahoo.com/bw/010207/nv_samarit_2.html


DISCLAIMER: New Pennies is a financial advisory network focusing
on high-growth companies with the intent to offer its subscribers a great
investment reward. It is an otcbb penny stock pick newsletter and
is not affiliated with any broker or dealer and is not a registered investment
advisor. The information contained in this publication is for informational
purposes only and is neither an offer to sell nor a solicitation of any offer
to buy securities. Investment in smallcap companies is considered
extremely speculative and may result in the loss of some or all of any
investment made in these companies. Investors should use the information
contained in this publication as a starting point for conducting additional
research on the featured company in order to allow the investor to form
their own opinion regarding the featured company. New Pennies holds
twenty thousand shares of the mentioned stock. Since we have a
position in SPHC there is an inherent conflict of interest in our statements
and opinions and therefore such statements and opinions cannot be
considered independent. We will benefit from any increase in price for SPHC.
We may liquidate our position at any time; before, during or after the
dissemination of this stock alert. Readers of this publication are cautioned
not to place undue reliance on forward-looking statements, which are based
on certain assumptions and expectations, that may or may not actually
occur, and involve various risks and uncertainties, that could cause results
to differ materially from those set forth in the forward-looking statements.
We are in no way directly affiliated with the above mentioned company.


If you wish to be unsubcribed from this newsletter email newpennies@excite.com
